Wall Street’s Best Investments Top Picks Daily Alert – 7/21/20
Here is a Top Picks update we missed, on our fourth-place winner, a company that is making great progress with an Alzheimer’s drug.
Read More
BI Research is edited by Tom Bishop, who developed the roots of the BI Ranking while earning his MBA in finance from Cornell University. Mr. Bishop has been actively investing in the stock market for over 40 years, having experienced several bear markets and countless 10-20% corrections since 1969. BI Research began publishing in 1981 and has been published continually with the same editor since that time. Mr. Bishop does all the research himself using a fundamental approach and his time-tested BI Ranking System. He and BI Research have been written about in Forbes, The Wall Street Journal, The New York Times, Fortune, Money, Barrons, Business Week and countless local papers like the Miami Herald.
Here is a Top Picks update we missed, on our fourth-place winner, a company that is making great progress with an Alzheimer’s drug.
Read More
Despite the market’s recent declines, this security system company has announced some very good preliminary results for its last quarter.
Read More
This bio-pharma company is seeing fantastic results with its Alzheimer’s studies.
Read More
This engineering and consulting firm is eating up its competition.
Read More
This is a low-cost biomedical stock that has its hands in several potentially lucrative medications.
Read More
Two recommendations today—an energy company with an improving future, and some profit-taking.
Read More
Analysts expect this security device maker to grow 32.1% this year.
Read More
This home retailer beat analysts’ estimates by $.0.04 last quarter and is expected to grow at a 25% annual rate during the next five years.
Read More
Estimates are rising for this oil services company.
Read More
This supplier to the construction industry beat Wall Street’s earnings forecasts by $0.06 per share last quarter. Analysts are expecting 40%+ growth from the company this year.
Read More
Jim Cramer is also forecasting a “lift across the board” for home building companies, including this one.
Read More
This biotech stock is rated ‘Buy’ by Zacks, based on excellent cash flow and momentum.
Read More
Our first idea is expected to grow at double-digit rates this year, and our second recommendation is profit-taking.
Buy: Hudson Technologies (HDSN)
From BI Research
Hudson Technologies (HDSN) provides and recycles refrigerants including CFCs, HCFCs and HFCs used primarily in air conditioning and refrigeration, but also certain...
Read More
Sell: Dycom (DY)
From BI Research
Updated from WSBI 783, July 20, 2016
Dycom (DY), which has risen $38 since its February low, trades at a PE of 15.8 times the FY7/17 consensus while the move to 1 gigabyte service and to “Connect (rural) America” continues The...
Read More
Motley Fool recently recommended this pharma company, noting the possibility of “astronomical returns, yet significant risk” (as is the case with most biopharmas).
Anavex (AVXL)
From BI Research
By far my top pick for 2017 is Anavex (AVXL). The company’s lead drug Anavex 2-73 has just very...
Read More
Analysts are forecasting a 27% growth rate for this entertainment company this year. Earnings are scheduled to be announced on September 6.
Dave and Busters Entertainment, Inc. (PLAY)From BI ResearchDave and Busters Entertainment, Inc. (PLAY) is an 82 location casual restaurant concept where you go...
Read More
EPS estimates for this silica company are moving up, with 14 analysts raising their forecasts in the past 30 days. Barclays just initiated coverage on the shares with an ‘Overweight’ rating and a $50 target.
U.S. Silica (SLCA) From BI Research
U.S. Silica (SLCA) recently Q2...
Read More
This telecom infrastructure company beat estimates by $0.34 last quarter, and analysts are forecasting that the company will grow nearly 60% this quarter.
Dycom Industries Inc. (DY) From BI Research
Dycom Industries Inc. (DY), which installs infrastructure for telecoms and cable companies, including wireless companies, benefiting...
Read More
This biotech is showing up on the radar of Wall Street. The shares were recently recommended by Motley Fool, TheStreet.com and Forbes. And Singular Research just upgraded them to ‘Buy’. The company beat last quarter’s earnings estimates by $0.17. Our second recommendation today a..
Read More
This infrastructure company beat analysts’ estimates by $0.23 in the last quarter, and five analysts have increased their forecasts in the past 30 days. Our second recommendation is a sell for a lagging fund.
Buy: Dycom (DY) From BI Research
Back in the late ‘90s the...
Read More